BrainsWay Announces Presentations at Upcoming Investor Conferences

Rhea-AI Summary

BrainsWay, a leader in non-invasive brain disorder treatments, announced that CEO Christopher von Jako will present at two key conferences on September 15, 2020. The H.C. Wainwright 22nd Annual Global Investment Conference will take place at 2:00 PM ET, followed by the Cantor Fitzgerald Virtual Global Healthcare Conference at 10:00 AM ET on the same day. BrainsWay specializes in Deep Transcranial Magnetic Stimulation technology, with FDA approvals for conditions like major depressive disorder, obsessive-compulsive disorder, and smoking addiction.

CRESSKILL, N.J. and JERUSALEM, Sept. 02, 2020 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced non-invasive treatment of brain disorders, today announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 22^nd Annual Global Investment Conference and the Cantor Fitzgerald Virtual Global Healthcare Conference.

Presentation Details:

H.C. Wainwright 22^nd Annual Global Investment Conference
Date:                     Tuesday, September 15, 2020
Time:                     2:00pm Eastern Time

Cantor Fitzgerald Virtual Global Healthcare Conference
Date:                     Tuesday, September 15, 2020
Time:                     10:00am Eastern Time

About BrainsWay
BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neurostimulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology. The Company received marketing authorization from the U.S. Food and Drug Administration (FDA) for its products for a variety of patient populations, including in 2013 for patients with major depressive disorder (MDD), in 2018 for patients with obsessive-compulsive disorder (OCD), and in 2020 for patients with smoking addiction. BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders. To learn more, please visit www.brainsway.com

Contacts:
BrainsWay:
Judy Huber
SVP and Chief Financial Officer
Judy.huber@brainsway.com

Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com

FAQ

When will BrainsWay's CEO present at the H.C. Wainwright Conference?

BrainsWay's CEO will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 2:00 PM Eastern Time.

What is the focus of BrainsWay's presentations at the conferences?

The presentations will focus on BrainsWay's advancements in non-invasive treatments for brain disorders, particularly its Deep TMS technology.

What time is BrainsWay's presentation at the Cantor Fitzgerald Conference?

BrainsWay's presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference is scheduled for September 15, 2020, at 10:00 AM Eastern Time.

What technologies does BrainsWay specialize in?

BrainsWay specializes in Deep Transcranial Magnetic Stimulation (Deep TMS) technology for treating various brain disorders.

What conditions has BrainsWay's technology received FDA approval for?

BrainsWay's technology has received FDA approval for major depressive disorder, obsessive-compulsive disorder, and smoking addiction.